FIELD: medicine; pharmaceuticals.
SUBSTANCE: The invention relates to an antibody against the 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable to testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgous monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgous 5T4 antigen. Besides, the invention relates to use of the antibodies and corresponding ADCs in the treatment of solid tumours and hematologic malignancies.
EFFECT: antibodies against 5t4 and antibody-drug conjugates are offered.
10 cl, 3 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | 2015 |
|
RU2670157C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| NON-LINEAR SELF-SPLITTING LINKERS AND THEIR CONJUGATES | 2017 |
|
RU2755899C2 |
| HUMANISED TAU ANTIBODIES IN ALZHEIMER DISEASE | 2015 |
|
RU2730668C2 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
